Last Updated: May 2, 2026

Profile for European Patent Office Patent: 4035664


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for European Patent Office Patent: 4035664

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,071,066 Oct 10, 2034 Stemline Therap ORSERDU elacestrant hydrochloride
10,420,734 Oct 3, 2036 Stemline Therap ORSERDU elacestrant hydrochloride
11,779,552 Oct 10, 2034 Stemline Therap ORSERDU elacestrant hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Key insights for pharmaceutical patentability - European Patent Office patent EP4035664

Last updated: April 28, 2026

EP4035664: Scope, Claims, and European Patent Landscape

EP4035664 is a European Patent Office (EPO) patent publication that sits in a crowded and fast-moving drug and life-sciences patent landscape. The available prompt does not include the EP4035664 publication text, bibliographic data (applicant, priority, filing dates), claim set, or any legal status and citation record. Without the actual published claims, claim numbering, and the EPO/INPADOC family data, a complete and accurate scope-and-landscape analysis cannot be produced under the operating constraints.

What is the scope of EP4035664 based on its claims?

No claim text or summary is provided. A scope analysis requires the independent claims and their dependent claim structure (including claim dependencies, claim terms, definitions, and any Markush language) to determine:

  • The active ingredient(s) or therapeutic target scope
  • The formulation/device/administration route scope
  • The dosing or regimen scope (if any)
  • The parameter constraints (e.g., particle size, solubility, stability, purity)
  • The breadth of composition and method claims
  • Any enforceable limitations (process steps, selection criteria, patient subsets)

No such information is included in the request content.

What do the claims cover (and what do they exclude)?

No claim set is provided. A defensible claim-by-claim coverage map needs:

  • Exact claim language
  • Definitions and recited alternatives
  • Negatives or exclusions (if used)
  • Coverage boundaries (ranges, thresholds, “comprising” vs “consisting of” language)
  • Whether claims are for product, method, use, or process

Without the claims, exclusions and enforceable boundaries cannot be determined.

How does EP4035664 position vs the existing European drug patent estate?

A landscape analysis requires at minimum:

  • EPO publication numbers in the same family and nearby families
  • Citation chain and forward citations
  • Competitor portfolios at the EPO for the same target or drug class
  • Status filters (granted, refused, withdrawn, lapsed) across EP family members
  • Jurisdiction-specific enforcement status (national phase grants in key EPC states)

No landscape inputs (citations, family, legal status, or competitor identifiers) are present.

What is the key prior art and who is likely impacted?

No prior-art list, search report, or cited documents are provided. Without citations from the EPO search report or published prosecution history, it is not possible to identify:

  • Which documents are most relevant (X/Y/A categories)
  • Which claim elements are anticipated or rendered obvious
  • Which competitors own close families
  • Which claim elements likely drive novelty/inventive step

European enforcement and timing

An enforcement window analysis requires:

  • Filing date, priority date, and publication date
  • Whether the patent is granted and in which states
  • Whether SPC-related rights exist (where applicable)
  • Any adjustments or validations
  • Legal events (opposition, limitation, withdrawal, lapse)

None of these dates and events are provided.

Claim-scope and litigation risk framework (what can be concluded from the request)

Given the absence of EP4035664’s actual claims and legal/citation data, the only accurate conclusion under the constraints is that no complete, verifiable analysis can be produced.

What is not available in the provided material

Required artifact Needed for Not provided
Claim text (independent + dependent claims) Scope mapping Missing
Claim numbering and dependencies Determine enforceable breadth Missing
Priority and filing dates Timelines, novelty window Missing
Bibliographic data (applicant/inventors/assignee) Competitor mapping Missing
EPO search report / cited documents Prior-art identification Missing
INPADOC family data Family breadth and countries Missing
Legal status (grant/opposition/lapse) Enforcement feasibility Missing
Forward citations Identify design-around and later filings Missing

Key Takeaways

  • EP4035664’s scope and enforceable claim boundaries cannot be analyzed without the published claim set and bibliographic/legal data.
  • A credible European patent landscape requires citations, family data, and legal status; none are included.
  • No litigation-risk, competitor impact, or prior-art positioning can be stated based on the provided prompt content.

FAQs

  1. Can you provide a claim-by-claim scope analysis of EP4035664 from this request?
    No. The request contains no EP4035664 claim text or claim list.

  2. Can you map EP4035664 to prior art and determine novelty/inventive step drivers?
    No. The request contains no EPO search report citations or cited document set.

  3. Can you identify which competitors in Europe are most impacted by EP4035664?
    No. The request contains no applicant/assignee details or citation-linked competitor families.

  4. Can you assess EP4035664’s enforcement likelihood across EPC states?
    No. The request contains no grant status, opposition outcomes, validations, or legal events.

  5. Can you estimate patent-term or SPC-related timing for EP4035664?
    No. The request contains no priority, filing, grant, or SPC/validation information.


References

[1] European Patent Office. EP4035664 (publication data and claims not included in provided prompt).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.